Real-world effectiveness, safety and immunogenicity of ocrelizumab in turkish multiple sclerosis patients: a single-center experience for 4-year follow-up-Reference-Cited by-同舟云学术

Real-world effectiveness, safety and immunogenicity of ocrelizumab in turkish multiple sclerosis patients: a single-center experience for 4-year follow-up

Published:2024-05-20 Issue:4 Volume:124 Page:1385-1391
ISSN:0300-9009
Container-title:Acta Neurologica Belgica
language:en
Short-container-title:Acta Neurol Belg

Author:

Erdogan Tugba,Cansu Cagri,Kocer Belgin,Akkaya Sedanur,Kokmen Helin

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s13760-024-02572-3.pdf

Reference19 articles.

1. Goodin DS (2014) The epidemiology of multiple sclerosis: insights to disease pathogenesis. Handb Clin Neurol 122:231–266

3. Stashenko P, Nadler LM, Hardy R, Schlossman SF (1980) Characterization of a human B lymphocyte-specific antigen. J Immunol 125(4):1678–1685

4. Seery N, Sharmin S, Li V et al (2021) Predicting infection risk in multiple sclerosis patients treated with ocrelizumab: a retrospective cohort study. CNS Drugs 35(8):907–918

5. Ciardi MR, Iannetta M, Zingaropoli MA et al (2018) Reactivation of hepatitis B virus with immune-escape mutations after ocrelizumab treatment for multiple sclerosis. Open Forum Infect Dis 6(1):ofy356

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Faces of “Too Late”—A Surprisingly Progressive Cohort of “Stable” Relapsing Remitting Multiple Sclerosis Patients;Medicina;2024-08-26